Renal Cell Carcinoma

First-line systemic therapy in metastatic renal cell carcinoma

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Lernziel: Recognise the most appropriate first-line treatment options for patients with advanced or metastatic renal cell carcinoma (RCC), as well as comprehend factors that impact the selection of first-line systemic therapy for these patients, e.g., risk group, performance status, histology, extent of disease.
Fachgebiet: Medical oncology, Clinical oncology, (Urology)
Zielpublikum: Specialists (CME: basic, intermediate), Residents (senior)
Letzte Aktualisierung: August 2024
Hintergrund:

Regulatory approval status of drugs for the treatment of advanced/metastatic RCC, mentioned in the CME courses on first- and later-line management (status 29 July 2024)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.